EC green light for Rhythm Pharma's Imcivree

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) yesterday announced that the European Commission (EC) has expanded the marketing authorization for Imcivree (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adult and pediatric patients six years of age and older.

“Patients and families have long endured a significant need for a therapy to address the burdens of hyperphagia and severe obesity often associated with BBS,” said Dr Philip Beales, University College London, UCL Great Ormond Street Institute of Child Health, adding: “Having new treatment options available can help address the physical and emotional aspects of this devastating disease, offering patients and their families relief and improved quality of life.”

Sales forecast